Intellia Therapeutics provides Phase 3 updates for NTLA-2002 and nex-z studies

Intellia Therapeutics, Inc.

HAELO study enrollment on track; expect completion Q3 2025, BLA submission H2 2026, potential US launch 2027.
MAGNITUDE-2 study of nex-z for ATTRv-PN progressing; BLA submission by 2028, potential US launch 2029.
MAGNITUDE study for nex-z in ATTR-CM enrolled ~365 of 765 patients; enrollment completion expected early 2027.
Over 200 patients dosed with nex-z in MAGNITUDE; adverse events similar to Phase 1; one asymptomatic grade 4 liver elevation resolving.

item 7.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.